On 9/8/25, Seres Therapeutics Inc (NASDAQ: MCRB) stock enjoyed a major increase of 18.0%, closing at $22.85. Moreover, exceptionally high trading volume at 669% of normal accompanied the advance. The stock has risen 20.3% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Seres Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment